NCT04755946 is a Phase 3 clinical trial of Roflumilast in Diabetic Nephropathies, sponsored by Tanta University.

Who is sponsoring NCT04755946?

NCT04755946 is sponsored by Tanta University.

What drugs are being tested in NCT04755946?

Interventions in NCT04755946: Roflumilast, Placebo.

What condition does NCT04755946 study?

NCT04755946 studies Diabetic Nephropathies.

Is NCT04755946 still recruiting?

NCT04755946 is currently status unknown. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT04755946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Possible Role of Roflumilast in Diabetic Nephropathy

Status unknown Phase 3 Last updated 16 February 2021

What this trial tests

Phase 3 trial testing Roflumilast in Diabetic Nephropathies in 48 participants. Status unknown.

Timeline

10 March 2021

Primary endpoint
10 June 2021

10 July 2021

Quick facts

Lead sponsor	Tanta University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	48
Start date	10 March 2021
Primary completion	10 June 2021
Estimated completion	10 July 2021

Drugs / interventions tested

Roflumilast (ROFLUMILAST) — full drug profile →
Placebo

Conditions studied

Diabetic Nephropathies — all drugs for Diabetic Nephropathies →

Sponsor

Tanta University

Who can join

Adults 18 to 65, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

adding roflumilast to the standard therapy for diabetic nephropathy and studying the progression of many outcomes including urinary albumin to creatinine ratio, estimated GFR, biomarkers of diabetic nephropathy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of podocyte injury and implications for diabetic nephropathy.
Barutta F, Bellini S, Gruden G. · · 2022 · cited 142× · PMID 35415751 · DOI 10.1042/cs20210625
Clinical Implication of Phosphodiesterase-4-Inhibition.
Schick MA, Schlegel N. · · 2022 · cited 56× · PMID 35163131 · DOI 10.3390/ijms23031209

Verify or expand the search:

Other trials of Roflumilast

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06977711 — Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large · Phase 1 · recruiting
NCT06860958 — Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients · Phase 3 · recruiting
NCT07174011 — Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the T · Phase 4 · completed
NCT06440473 — Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin · Phase 4 · recruiting

Other recruiting trials for Diabetic Nephropathies

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07187713 — ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases · Phase 4 · recruiting
NCT06778018 — Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy · NA · recruiting
NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
NCT06431477 — Efficacy and Safety of Telmisartan Compared With Losartan · Phase 4 · recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04755946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04755946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing